Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avacopan in Crescentic IgA Nephropathy
NCT06676579Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avacopan in IgA nephropathy (IgAN), sponsored by Mayo Clinic. Started Jun 2025; status: recruiting.
02
Drugs
avacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06676579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676579.